50693-75-9

Usage

Uses

Used in Pharmaceutical Industry:
3-Phenyl-6-(piperazin-1-yl)pyridazine is used as a key intermediate in the development of drugs targeting neurological and psychiatric disorders. Its piperazine group allows it to interact with biological receptors, making it a promising candidate for the creation of new therapeutic agents.
Used in Research Applications:
In the field of research, 3-Phenyl-6-(piperazin-1-yl)pyridazine serves as a valuable compound for studying the interactions between molecules and biological receptors, contributing to the advancement of scientific knowledge and the development of novel therapeutic strategies.
Used in Material Science:
3-Phenyl-6-(piperazin-1-yl)pyridazine is used as a component in the development of new materials due to its unique structural and chemical properties. Its potential applications in this field may include the creation of innovative materials with specific properties tailored for various industries.
Used in Catalyst Development:
3-PHENYL-6-(PIPERAZIN-1-YL)PYRIDAZINE also has potential uses in the development of new catalysts, which are essential for accelerating chemical reactions in various industrial processes. Its unique structure may contribute to the design of more efficient and selective catalysts.
Used in Agrochemicals and Pesticides:
3-Phenyl-6-(piperazin-1-yl)pyridazine may also find applications in the field of agrochemicals and pesticides, where it could be utilized in the development of new products to protect crops and enhance agricultural productivity. Its interaction with biological receptors may provide a basis for the creation of effective and targeted agrochemical solutions.

Upstream product

• 110-85-0 piperazine 
• 20375-65-9 3-chloro-6-phenylpyradazine 

Downstream Products

• 161331-20-0 4-<(4-phenylpyridazinyl)piperazin-1-yl>-1,1-ethylenedioxy-1-(4-fluorophenyl)butane 

Relevant academic research and scientific papers

HETEROCYCLIC DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS

Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I): where x, y, G, J, K, L, M, V R2, R3, R4, R5, R5a, R6, R6a, R7, R7a, R8 and R8a are defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.

Synthesis and evaluation of pyridazinylpiperazines as vanilloid receptor 1 antagonists

A series of pyridazinylpiperazines were synthesized and evaluated for VR1 antagonist activity in order to improve upon the pharmaceutical and pharmacological properties of BCTC. A structurally biased chemical library of pyridazinylpiperazine analogs was prepared in an effort to improve the pharmaceutical and pharmacological profile of the lead compound N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine-1(2H) -carboxamide (BCTC). The library was evaluated for VR1 antagonist activity in capsaicin-induced (CAP) and pH 5.5-induced (pH) FLIPR assays in a human VR1-expressing HEK293 cell line. The most potent VR1 antagonists were found to have IC50 values in the range of 9-200 nM with improved pharmaceutical and pharmacological profiles versus the lead BCTC. These compounds represent possible second-generation BCTC analogs.

Pyridazine derivatives XII. Synthesis and antipsychotic-antidepressant activity of some butyrophenone derivatives of 6-phenylpyridazine

We have synthesized several 3-amino-6-phenyl pyridazines in which the amino substituent is a linear butyrophenone moiety (compounds 8 and 10), a cyclic butyrophenone moiety (compound 3), or a phenylpiperazine fragment (compound 2).Compound 8 potently inhi